Biomarkers in Blood May Predict Alzheimer's Disease Progression

A study published in *Nature Medicine* has identified small loops of genetic material called circular RNAs (circRNAs) as potential early indicators of Alzheimer’s disease (AD) symptom onset. Researchers found that elevated levels of specific circRNAs in blood samples were associated with a nearly threefold increased risk of developing AD symptoms within a follow-up period, outperforming traditional biomarkers like amyloid-beta and tau proteins in sensitivity. This discovery could enhance early detection efforts and improve the accuracy of predicting cognitive decline.

The research, conducted across over 1,000 participants, analyzed circRNA levels in blood plasma and correlated them with clinical outcomes over several years. Elevated circRNA concentrations were observed up to two years before the emergence of AD symptoms, suggesting these molecules respond more dynamically to the disease’s progression. Unlike amyloid or tau, which accumulate gradually in the brain, circRNAs appear to reflect real-time pathological changes, offering a more immediate signal of impending cognitive deterioration. The findings highlight the potential of circRNAs as a novel class of biomarkers for tracking AD risk and monitoring treatment efficacy.

The study underscores the need for further validation in diverse populations and clinical settings to establish circRNAs as reliable diagnostic tools. If confirmed, their integration into routine screening could enable earlier interventions and personalized therapeutic strategies for at-risk individuals. However, researchers caution that additional studies are required to clarify the biological mechanisms linking circRNAs to AD pathology and to refine their predictive accuracy.